| Name | Title | Contact Details |
|---|
Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.
Interface Biologics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.
Mosaic`s biopharmaceutical teams turn ideas into reality. We provide experienced biopharma leadership and cross-functional teams to accelerate your protein therapeutic research and development program